These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Craig WA; Andes DR Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659 [TBL] [Abstract][Full Text] [Related]
6. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae. Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934 [TBL] [Abstract][Full Text] [Related]
8. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Jones RN; Barry AL Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422 [TBL] [Abstract][Full Text] [Related]
9. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634 [TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715 [TBL] [Abstract][Full Text] [Related]
11. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. Bonfiglio G; Livermore DM J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865 [TBL] [Abstract][Full Text] [Related]
12. An evaluation of the in vitro activity of piperacillin/tazobactam. Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825 [TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Wiskirchen DE; Crandon JL; Furtado GH; Williams G; Nicolau DP Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Peterson LR Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria. Chang SC; Hsu LY; Luh KT; Hsieh WC J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689 [TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Fass RJ; Prior RB Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904 [TBL] [Abstract][Full Text] [Related]